PASG
What one share of Passage Bio holds
Biological Products, (No Diagnostic Substances)
We are a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions.
Passage Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$11.31 |
|---|---|
| Cash and investments | $7.51 |
| Book value | $1.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$10.77 | — | −$9.42 | — | −$13.10 |
| 2020 | — | −$2.91 | — | −$2.09 | — | $6.68 |
| 2021 | — | −$3.48 | — | −$2.38 | — | $5.87 |
| 2022 | — | −$2.50 | — | −$2.17 | — | $3.69 |
| 2023 | — | −$1.86 | — | −$1.43 | — | $2.03 |
| 2024 | — | −$21.04 | $0.01 | −$15.59 | — | $19.38 |
| 2025 | — | −$14.35 | — | −$9.93 | — | $5.89 |